Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05531656 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
A Phase 2 study of Early Alzheimer's Disease, sponsored by Cognition Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT05531656 is a Phase 2 study of Early Alzheimer's Disease that is active but no longer recruiting, run by Cognition Therapeutics. The registered enrollment target is 540 participants, below the 1,025-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05531656, a Phase 2 study of Early Alzheimer's Disease, is active but no longer recruiting, sponsored by Cognition Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CT1812
Study Locations (20)
Florida
- Brain Matters Research - Delray Beach
- Neuropsychiatric Research Center of Southwest Florida - Fort Myers
- Mayo Clinic,Jacksonville - Jacksonville
- JEM Research Institute - Lake Worth
- K2 Medical Research, LLC - Maitland
- Advanced Clinical Research Network, Corp - Miami
- Charter Research - Orlando
- Headlands Research Orlando - Orlando
- Brain Matters Research Stuart - Stuart
- University of South Florida - Tampa
- Conquest Research, LLC - Winter Park
California
- University of California - Irvine
- Stanford University - Palo Alto
- Sutter Institute for Medical Research - Sacramento
Arizona
- Banner Alzheimer's Institute - Phoenix
- Banner Sun Health Research Institute - Sun City
District of Columbia
- Georgetown University - Washington D.C.
- Howard University - Washington D.C.
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05531656
The ClinicalTrials.gov registry entry for NCT05531656 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,025-participant average among 7 other Early Alzheimer's Disease trials with a reported enrollment target (47% lower). The listed sponsor is Cognition Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Alzheimer's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05531656 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05531656 about?
NCT05531656 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease". This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
What is the current status of trial NCT05531656?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 540 participants. The study started on 2023-06-28. Estimated completion is 2027-04.
What conditions does trial NCT05531656 study?
This clinical trial studies the following conditions: Early Alzheimer's Disease.
What interventions are being tested in trial NCT05531656?
The interventions under investigation include: Placebo (DRUG), CT1812 (DRUG).
Who is sponsoring clinical trial NCT05531656?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05531656 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
RECRUITING · Phase 2
-
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
RECRUITING · Phase 3
-
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.